Z0011:

A randomized trial of axillary node dissection in women with clinical T1 or T2 N0 M0 breast cancer who have a positive sentinel node

ClinicalTrials.gov Identifier: NCT00003855

Study Background

Trial Design: This is a phase III randomized trial to determine the effectiveness of removing lymph nodes in the armpit in treating women who have stage I or stage IIA breast cancer. Women with clinical stage T1 or T2 N0 M0 breast cancer who are found to have a sentinel node (SN) containing metastatic breast cancer through sentinel lymph node dissection (SLND) with breast conserving therapy (BCT), as documented on frozen section, touch prep, or permanent section evaluation by hematoxylin and eosin (H&E) staining, will be randomized to one of two Arms:

- Arm 1: Completion axillary lymph node dissection (ALND), followed by whole breast radiation therapy and, if indicated, systemic adjuvant therapy
- Arm 2: No immediate additional axillary surgery or axillary-specific radiation, followed by whole breast radiation therapy and, if indicated, systemic adjuvant therapy.

Objectives:

	 Primary <i>Long term:</i> To assess whether overall survival for patients randomized to Arm 2 (no immediate ALND) is essentially equivalent to (or better than) than that for patients assigned to Arm 1 (completion ALND). <i>Short term:</i> To quantify and compare the surgical morbidities associated with SLND plus ALND versus SLND alone.
Stratification Factors:	 Age: ≤ 50 or > 50. Estrogen Receptor (ER) status: positive or negative. Tumor size: ≤ 1 cm, > 1 cm or ≤ 2cm, or >2 cm.
Study History:	1/31/2002Activation Date12/15/2004Close DateAug 2007Primary Completion DateFeb 2011Study Completion Date

Publication Information

Analysis Type:	Primary Endpoint Analysis
PubMed ID:	21304082
Citation:	Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M. Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node MetastasisA Randomized Clinical Trial. <i>JAMA</i> . 2011;305(6):569-575. doi:10.1001/jama.2011.90
Associated Datasets:	NCT00003855_D1_(efficacy)

Dataset Information

Dataset Name:NCT00003855_D1_(efficacy)Description:The NCT00003855_D1_(efficacy) contains all manuscript data on treated
patients only (n=856).

NCT00003855_D1_(efficacy) Data Dictionary*

*Throughout the dictionary NA refers to any value that was not collected or otherwise missing.

Variable Description	Variable Name	Code	Notes
Patient identifier	patref		If data is submitted to NCTN Navigator for this trial, this ID will be able to tie clinical data with NCTN submission.
Patient age in years at registration	age		Participants who are 90 years old or older were categorized as >=90 in the code
Arm	arm	1=ALND 2=No ALND	Missing values indicate the data was not available and not reported as part of the manuscript.
Arm Label	armlabel	ALND No ALND	
Clinical T stage	stage	1 = T1 2 = T2	
Local recurrence indicator	local	1=yes, 0=Patient was not identified as having local recurrence.	
Regional recurrence indicator	regional	1=yes, 0=Patient was not identified as having regional recurrence.	
Distant recurrence indicator	distant	1=yes, 0=Patient was not identified as having distant recurrence.	
Vital Status indicator	fu_stat	1=dead 0=alive	
Recurrence indicator	pg_stat	1=recurrence 0=no recurrence	
New primary indicator	nprim_stat	1=new primary 0=no new primary	
Days between registration and date of last known	fu_time	Numeric	

alive or date of death			
Years between registration and date of last known alive or date of death	fu_yrs	Numeric	
Days between registration and date of recurrence or last recurrence assessment	pg_time		
Disease Free Survival indicator	dfs_stat	1=recurred or died 0=not recurred or dead	
Days between registration and recurrence or death	dfs_time	Numeric	
Number of sentinel nodes removed	sln		
Number of positive SLN	possln		
Number of axillary nodes removed	aln		
Number of positive ALN	posaln		
Total lymph nodes removed	tln		
Primary tumor-breast	PTBRST	1=Right 2=Left	
Pathologic tumor size	PATHTSZ		As measured in centimeters (cm). Note: Due to data cleaning efforts, a minor discrepancy was found reported in Table 1 in the publication.
Primary tumor type: ductal	PTTYP1	1=Infiltrating ductal, 0=Participant did not report having Infiltrating ductal disease.	
Primary tumor type: lobular	PTTYP2	1=Infiltrating lobular, 0=Participant did not report having Infiltrating lobular disease.	
Primary tumor type: other	РТТҮР3	1=Other tumor type, 0=Participant did not report having other tumor type.	
Margin tumor free	MARGTUM	1=Yes 2=No	

Adjuvant radiation therapy	rt	1-voc	
• •	11	1=yes	
given		0=no	
Adjuvant hormonal	hormone	1=yes	
therapy given		0=no	
Adjuvant chemo therapy	chemo	1=yes	
given		0=no	
Adjuvant chemo or	adjther	1=yes	
hormonal therapy given		0=no	
Tumor type	hist1	1=Infiltrating ductal	
		2=Infiltrating lobular	
		3=Other	
Total number of positive	totposln	0=0	Note: A discrepancy from the
SLNs and ALNs		1=1	manuscript is one patient in the
		2=2	SLND group moved from the 1
		3=3	positive node to the 4 or more
		$4 = \ge 4$	positive nodes category.
			The variable only includes
			where possln and posaln are
			both non-missing for the ALND
			group.